《大行》高盛升科伦博泰(06990.HK)目标价至561.4元 评级“买入”

阿斯达克财经
Jun 01

高盛发表研究报告指,科伦博泰生物-B(06990.HK) 在2026年美国临床肿瘤学会年会上口头报告核心产品芦康沙妥珠单抗(sac-TMT) III期OptiTROP-Lung05临床试验数据,结果在《柳叶刀》同步发布。该行认为,科伦博泰的研究数据坚实,足以支持监管部门核准,并为TroFuse-07第三期全球试验提供了强而有力的参照依据。该行上调科伦博泰2027至28年的每股盈测至7.49元和...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10